30 Sep 2015 09:07
Omega Diagnostics Group PLC
("Omega" or the "Company")
Grant of Options
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that yesterday evening its Remuneration Committee awarded Colin King, Chief Operating Officer, 1,200,000 share options under the Company's EMI Share Option Scheme. Half of these are subject to performance criterion 1 and half subject to performance criterion 2.
The Options have been awarded at an exercise price of 13.0p (closing mid-market price on 28 September 2015). Following the grant yesterday, these options represent Colin King's only interest in the Company.
Performance conditions:
Performance criterion 1: The options have a three year vesting period and after they are fully vested, they cannot be exercised until the share price has been at 50p or higher on at least one occasion at any time on or after the vesting period.
Performance criteria 2: In addition to performance criterion 1, the Company's adjusted earnings per share must exhibit a 10% cumulative growth rate over the three-year period beginning 1 April 2016.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive |
|
Kieron Harbinson, Group Finance Director Jag Grewal, Group Sales and Marketing Director | www.omegadiagnostics.com |
|
|
finnCap Ltd | Tel: 020 7220 0500
|
Geoff Nash/James Thompson (Corporate Finance) Mia Gardner (Corporate Broking) |
|
|
|
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
|
|
|
|